HeartBeam Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
28.2%projected annual EPS growth
Analyst Coverage
4analysts covering
FY Revenue (est.)
$700Knext fiscal year
FY EPS (est.)
-$0.38next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Net Cash Used in Operating Activities Quarterly-3.6MTarget: Reduction in cash burn rate through disciplined cost management
Cash and Cash Equivalents Quarterly2MTarget: Sufficient runway supplemented by the $11.5 million gross proceeds from the April 2026 public offering
FDA Cleared Indications Annually2.0Target: Expansion into heart attack detection and continuous 12-lead patch monitoring
Watch Items
- ALIGN-ACS Pilot Study CompletionTrigger: Completion of study in Q3 2026Action: Finalize FDA pivotal study design in Q4 2026 to prepare for the ALIGN-ACS II pivotal study in 2027
- Commercial Adoption in Concierge CardiologyTrigger: Initial staged rollout with ClearCardio and other premier concierge practicesAction: Monitor patient enrollment, physician recommendation rates, and subscription-based recurring revenue generation
- 12-Lead ECG Patch Partnership DiscussionsTrigger: Initiation of partnership discussions in Q3 2026Action: Secure strategic collaborations to accelerate development and commercialization of the continuous wear patch
Research as of 19 Jun 2026